Guangdong Hybribio Biotech Co., Ltd. Overview
Hybribio is a Chaozhou-based, founder-controlled Chinese molecular-diagnostics company that built its franchise on HPV genotyping using a proprietary flow-through hybridisation platform originally licensed from the University of Hong Kong. Its HPV21 kit was the first HPV test in China to receive a new-drug certificate and its core patent won the 18th China Patent Gold Award. The company later integrated downstream into independent clinical laboratories (27 licensed labs across China and Hong Kong) and, since 2024, a private hospital in Chaozhou. COVID-19 testing transformed its scale—revenue peaked at RMB 5.6 bn in FY2022—but the post-pandemic unwind, national volume-based procurement (VBP) of HPV-DNA tests, a VAT increase on reagents, and large impairments on pandemic-era government receivables produced losses in FY2024–FY2025. In H1 2026 it returned to a small profit. The investment case now hinges on receivable recovery, new-assay mix (methylation, pharmacogenomics, mRNA triage), lab restructuring, and a debt-light balance sheet supporting buybacks.
Company's own description (FY2025 Annual Report, paraphrased)
The company describes itself as a leading domestic integrated provider of molecular diagnostic products and services, organised around three mutually reinforcing business pillars: (1) molecular diagnostic products, (2) medical laboratory testing services, and (3) medical "big health" services. Products cover tumour early screening, infectious disease and hereditary disease testing—specifically oncology tests, communicable disease tests, maternal and child health management and birth-defect prevention—used in hospital clinical diagnosis, birth-defect prevention programmes and public-health screening. The laboratory network is positioned on molecular diagnostics as the core technology with high-end specialty testing (metagenomics, tumour early screening, tandem mass spectrometry, high-density gene chips) as the growth direction. The health-services pillar centres on Chaozhou Kaipu Kanghe Hospital and a physical examination centre, tied together through the "Kaipu Kanghe Medical Testing 5.0" (凯普康和医检5.0) system, which uses an internet hospital as the carrier and the national lab network as the fulcrum to serve both B2B and B2C customers.
Business model and revenue model
| Revenue stream | Model | Customers | Evidence (source, period) |
|---|---|---|---|
| Self-produced reagents & instruments (自产产品) | Product sales; direct sales to key hospitals plus buy-out distribution through annually contracted distributors | Public hospitals, maternal & child health (MCH) institutions, CDCs, screening programmes, distributors | H1 2026 self-produced product revenue RMB 173 M, gross margin 77.13% (2026 Interim, via CFI.cn) |
| Purchased (third-party) products (外购产品) | Resale | Same as above | H1 2026 RMB 11.07 M (2026 Interim) |
| Medical laboratory testing services | Fee-for-test outsourcing contracts; co-built hospital labs | Hospitals (incl. primary care), government health commissions (2020–22 pandemic testing) | H1 2026 RMB 95.46 M, gross margin 13.58% (2026 Interim) |
| Medical services (hospital) | Fee-for-service clinical care, health check-ups, online consultations | Patients, corporate check-up clients, insurers (planned) | FY2025 hospital revenue RMB 27.49 M; H1 2026 RMB 20.90 M, gross margin −38.40% |
| Other | Leasing, misc. | — | H1 2026 RMB 2.0 M |
There is no subscription or licensing revenue of significance disclosed. The company's IT platforms (two-cancer screening management, birth-defect screening management, pathology management, LIS, regional lab platform, medical expert database) are positioned as solution add-ons, but separate revenue is not disclosed.
Value-chain position
Hybribio sits across three links of the IVD value chain: (i) upstream assay development and reagent/instrument manufacturing (Chaozhou and Guangzhou production bases, ISO 13485/MDSAP-certified); (ii) midstream testing services via its own ICL network; and (iii) downstream care delivery via a hospital and internet hospital. It is also attempting to move further upstream through minority investments in sequencing-instrument developers (Chengdu Jinshi Zhixu, Shenzhen Salus) and into therapeutics (two anti-HPV topical drug candidates).
End-markets
Women's health (cervical cancer screening, reproductive tract infections), birth-defect prevention (thalassaemia, hereditary deafness, G6PD deficiency, chromosomal aneuploidy, SMA), infectious disease (HBV, respiratory pathogens, CMV, GBS), pharmacogenomics/precision medication (clopidogrel, warfarin, statins, folate, psychiatric drugs, APOE for Alzheimer's risk), and cancer early detection (cervical, bladder, nasopharyngeal methylation). Geographically, the business is overwhelmingly domestic (overseas revenue RMB 13.34 M in H1 2026, ~4.4% of revenue).
Independent characterisation
Hybribio is best understood as a niche HPV/women's-health diagnostics franchise that over-expanded into labour- and capital-intensive lab services during the pandemic and is now in a multi-year right-sizing. The reagent business remains highly profitable at the gross level (74.6% gross margin in H1 2026) despite VBP, whereas lab services barely cover direct costs (13.6% gross margin) and the hospital is loss-making. The single largest driver of reported earnings in 2024–2026 has not been operations but the provisioning cycle on ~RMB 1.08 bn of gross pandemic-era receivables from local governments—an item whose reversal (H1 2026 credit-impairment write-back of RMB 30.4 M) now flatters profit just as its build-up depressed FY2024.
Strategy
Stated strategy themes (FY2025 AR)
"Three business pillars" synergy: molecular diagnostic products, medical lab services and medical health services.
"Kaipu Kanghe Medical Testing 5.0": integrates the three pillars using the hospital as cornerstone, the internet hospital as carrier and 20+ labs as fulcrum; four business lines (tumour early screening; online B2C testing; full-cycle cancer management; diabetes management).
"Nucleic Acid 99" (and "999") strategy: continuous launch of new nucleic-acid assays; >60 projects in development across infectious disease, genetics, metagenomics, methylation and mass spectrometry.
2026 operating theme: "Restructure, upgrade, develop" — strengthen HQ direct management, empower provincial management groups, create a national bidding-management centre ("bid on everything, raise win rate"), rebuild national distributor system, launch national distributor recruitment for new products, push the industry chain down to consumers.
AI & data assetisation: roll out the "Wuxian" medical AI brain (Hybribio/ComeWell WuXian AI Brain); build a master-data platform across R&D, registration, screening, diagnosis, treatment and health management; pursue AI product registrations in tumour screening.
Internationalisation: more country registrations; Hong Kong lab as springboard to South-East Asia.
Initiatives in the last 24 months
| Initiative | Detail | Date | Source |
|---|---|---|---|
| Lab network restructuring | 31→27 labs; exit low-margin routine tests; focus on specialty testing | FY2025 | FY2025 AR |
| Kanghe hospital ramp-up | First full year; RMB 27.49 M revenue; internet hospital licence; 5 new departments and linac in 2026 | 2025–26 | FY2025 AR |
| Wuxian AI Brain | "Ten Shamans" digital-employee team covering service, data entry, interpretation, report review, alerting | 2,025 | FY2025 AR |
| Market Value Management System | Adopted by board | 10 Dec 2024 | 2026 Interim |
| Share buybacks | 2025 programme (treasury stock RMB 110.1 M at Sep 2025); 2026 programme RMB 75–150 M | 2025–26 | Q3 2025 report; Caiwen News |
| Receivable recovery drive | Executive-led task force; litigation; engagement with State Council departments; leverage local-government debt-swap policies | 2024–26 | FY2025 AR |
| Capex pacing | Suspension of Medical Science Park hospital and conference-centre construction | FY2025 | FY2025 AR |
| ESG/community | Up to RMB 30 M charitable donations (2026); RMB 20 M donated to Guangdong basic research joint fund (138 projects funded cumulatively) | 2026; cumulative | SZSE Q&A June 2026; FY2025 AR |
| Cultural platform | "Lingdong Humanities Network"; acquisition of the "Changguangli" media operator | Feb 2026 | FY2025 AR |
Medium-term targets / guidance
No quantitative revenue or margin guidance is published. Management's qualitative targets for 2026: improve lab-segment cost control, expand non-VBP HPV products (mRNA, methylation) and the four key product series, increase profitability overall. The company expects lab services and hospital to remain loss-making in the short term (FY2025 AR risk section).
Products & Services
Registration base at end-FY2025: 97 domestic device registrations/filings (34 Class III, 6 Class II, 56 Class I filings, 1 Hong Kong listed Class C), 59 CE certifications of which 26 under EU IVDR (FY2025 AR).
Molecular diagnostics — Cervical cancer / HPV franchise
| Product | Description & capability | Target customer | Status / notes |
|---|---|---|---|
| HPV21 genotyping kit | Flow-through hybridisation, 21 HPV types; first HPV test in China with a new-drug certificate; core patent won 18th China Patent Gold Award | Hospitals, screening programmes | Marketed; legacy flagship |
| HPV37 genotyping kit | Detects 37 types — company states most types among marketed HPV tests in China | Tertiary hospitals, epidemiology | Marketed |
| HPV12+2 | 14 high-risk types; first in China approved for primary cervical screening, co-testing and ASC-US triage claims beyond aided diagnosis | National "two-cancer" screening | Marketed; widely used in public screening |
| HPV14 genotyping | Covers the 14 high-risk types in the WHO cervical precancer screening guideline | Screening | Marketed |
| High-risk HPV E6/E7 mRNA test | Triage of ASC-US-positive cytology patients | Hospitals | Marketed; outside national VBP |
| Cervical cancer methylation test | Triage of HPV-positive women; registered device | Hospitals | Marketed; outside VBP |
| Usage metrics | Cumulative HPV test usage >83 M; ~8.6 M person-tests in FY2025; 10 consecutive WHO HPV LabNet proficiency rounds; >1,650 papers using the products | — | FY2025 AR |
| VBP position | Kaipu Chemical first by reported demand in national HPV-DNA VBP (3.37 M person-tests, 24.17%); competitive in 25 alliance provinces | — | FY2025 AR. Pricing model: VBP tender pricing; ex-factory prices fell sharply (exact prices not disclosed) |
Birth-defect prevention
| Product | Description | Status |
|---|---|---|
| Thalassaemia gene test | Flagship hereditary test (α/β-thalassaemia), cumulative ~4.4 M uses | Marketed; nanopore-sequencing version in development |
| Hereditary deafness susceptibility gene test | Cumulative ~3.4 M uses; company co-drafted NMPA industry standard; >300 deafness-gene demonstration bases | Marketed |
| G6PD gene test | Glucose-6-phosphate dehydrogenase deficiency (favism) | Marketed |
| CMV nucleic-acid test | Human cytomegalovirus | Marketed |
| Group B Streptococcus nucleic-acid test | Perinatal GBS | Marketed |
| Y-chromosome microdeletion test | Male infertility | Marketed |
| Chromosome (13/18/21/X/Y) multiplex STR kit (fluorescent PCR–capillary electrophoresis) | Detects seven aneuploidy types in amniotic fluid plus maternal cell contamination; co-developed with Guangdong Women and Children Hospital | Registered 4 Mar 2026 |
| SMA gene test | Spinal muscular atrophy (fluorescent PCR and MALDI-TOF platforms) | Clinical trial |
| HPV/thalassaemia cell-line reference materials | QC materials | Developed |
Reproductive tract infection (STD) and infectious disease
| Product | Description | Status |
|---|---|---|
| STD series (single, 2-plex, 3-plex, 10-plex) | Gonorrhoea, chlamydia, ureaplasma, M. genitalium, M. hominis, HSV-2 etc.; cumulative >4.85 M uses | Marketed |
| Vaginal microbiome 3-plex nucleic-acid kit | Vaginal microecology | Registration stage |
| Multi-pathogen reproductive-tract kits | Expansion of STD panel | Development |
| HBV gene test | Hepatitis B; usage +32.35% YoY in FY2025 | Marketed |
| HBV high-sensitivity test | Low viral-load detection | Clinical trial |
| Respiratory 6-plex | Influenza A/B, RSV, adenovirus, M. pneumoniae and others | Registered in FY2025 |
| Respiratory single-plex tests | Subsets of the above | Developed |
| SARS-CoV-2 nucleic-acid test | COVID-19 | Marketed (demand largely gone) |
| Norovirus nucleic-acid kit | Gastroenteritis | Registration stage |
| Chikungunya/dengue nucleic-acid kit | Arboviruses | Clinical trial |
Pharmacogenomics / precision medication
| Product | Gene targets | Use |
|---|---|---|
| Human CYP2C19 gene test | CYP2C19 | Clopidogrel response |
| CYP2C9 & VKORC1 gene test | CYP2C9, VKORC1 | Warfarin dosing |
| MTHFR gene test | MTHFR | Folate supplementation |
| ALDH2 gene test | ALDH2 | Nitroglycerin response, alcohol metabolism |
| APOE & SLCO1B1 polymorphism test | APOE, SLCO1B1 | Statin myopathy risk; Alzheimer's early risk assessment |
| Psychiatric drug-concentration tests | Mass-spec | Therapeutic drug monitoring |
| Vitamin and endocrine panels | Tandem mass spectrometry | LDT/lab use |
The nine "push" products (Y-microdeletion, CMV, GBS, G6PD, MTHFR, ALDH2, CYP2C9/VKORC1, CYP2C19, APOE/SLCO1B1) generated close to RMB 25 M in FY2025 (FY2025 AR).
Oncology early detection
| Product | Status |
|---|---|
| Cervical cancer methylation | Registered |
| Bladder cancer methylation | Clinical trial |
| Nasopharyngeal carcinoma methylation (3 patents/technologies licensed from Sun Yat-sen University Cancer Center) | Clinical trial |
| Endometrial cancer methylation | Research |
| Pan-cancer early screening service package (risk assessment → pan-cancer → single-cancer) | Offered via Kanghe 5.0 |
Instruments, consumables and IT
Sample processing, nucleic-acid extraction and molecular hybridisation instruments and consumables (exact models not disclosed in reviewed documents). Six IT platforms: two-cancer health management platform with cytopathology AI-assisted diagnosis, birth-defect screening management platform, pathology diagnosis management platform, medical laboratory LIS, Kaipu regional medical testing platform, Kaipu medical expert database. "Wuxian Medical AI Brain" (multimodal LLM + proprietary medical knowledge base + agent "digital employees") deployed for customer service, data entry, result interpretation and report review.
Therapeutics pipeline
| Candidate | Indication | Stage |
|---|---|---|
| Chloroquine phosphate gel (improved new drug) | HPV-induced skin warts, genital and perianal condyloma | Phase II completed; Phase III imminent (FY2025 AR; Sept 2026 IR) |
| Anti-HPV vaginal gel | High-risk HPV infection | Phase II |
Medical laboratory services
27 licensed labs; >85,000 m² floor space; several hundred high-end instruments (tandem MS, NGS, immunochemistry and molecular automation lines); ~2,000 test items across hereditary metabolic disease, infectious disease, molecular pathology, cytogenetics and genetic counselling, tumour genomics, pharmacogenomics, endocrinology, gynaecology and reproductive-tract metagenomics; CNAS/ISO 15189 quality system. Platforms: LC-MS/MS, nucleic-acid MS, ICP-MS, microbial MALDI; multi-channel qPCR, digital PCR, molecular POCT; pathogen mNGS and tNGS.
Medical "big health" services
Chaozhou Kaipu Kanghe Hospital: ~27 mu site, ~16,000 m² first phase, 200 planned beds (100 open); cores in oncology (led by CMO Prof. Li Xiaochuan, tenured professor of radiation oncology, Medical College of Wisconsin), orthopaedics, and health management; specialties in blood purification and digestive endoscopy; 16 clinical and 4 medical-technology departments, with oncology, psychiatry, general surgery, medical aesthetics and radiotherapy to be added in 2026; linear accelerator planned. Online: Kanghe internet hospital (licensed 2025), "Kaipu Tong" and "Kanghe Mall" WeChat mini-programs with >400 test/risk-assessment items; home nurse visits via partners. Kanghe 5.0 business lines: tumour early screening, online B2C testing, full-cycle cancer management, diabetes (chronic disease) management.
Financial Narrative
Sources: FY2021–FY2022 restated figures from FY2023 AR summary (restatement due to accounting-policy change); FY2023–FY2025 from FY2024 AR and FY2025 AR summary; gross profit and total net profit FY2024–FY2025 from Pharnexcloud filing extracts of the annual reports.
Income statement
Revenue CAGR FY2021–FY2025 (calc.): −29.2% p.a.
Quarterly run-rate
2026 year-to-date: Q1 2026 revenue RMB 125.8 M with net profit of about −RMB 2.8 M (SZSE.io summary of Q1 report); H1 2026 revenue RMB 300.0 M (−4.74% YoY) and attributable net profit RMB 31.26 M (vs −RMB 89.59 M), implying Q2 2026 revenue of ~RMB 174 M and attributable profit of ~RMB 34 M (calc.).
H1 2026 income-statement detail (2026 Interim)
Commentary: the H1 2026 turnaround is of mixed quality. Of a ~RMB 120 M swing in attributable profit, roughly RMB 88 M came from the credit-impairment swing (−57.6 → +30.4), RMB 42 M from halved selling expense, RMB 16 M from higher FX-driven financial income and RMB 6 M from fair-value gains. Gross profit actually fell slightly (RMB 148 M → RMB 142 M).
Balance sheet
Additional verified balance-sheet items:
Net debt is strongly negative (net cash of roughly RMB 0.9–1.0 bn at end-2025 on verified items: RMB 1,038.7 M cash/deposits less ~RMB 97 M borrowings, calc.).
Cash flow
FY2021 OCF is derived from the reported FY2022 OCF of RMB 1,309.2 M and its disclosed 107.37% growth (calc.). FY2025 cash received from sales of goods and services was RMB 1,078.0 M—1.6x revenue—evidencing collection of old receivables.
Ratios
Leverage is immaterial (debt ratio ~12%, borrowings <RMB 100 M), so interest-coverage risk is low; the relevant working-capital metric is receivables, where net receivables (RMB 697 M) exceed a full year of revenue.
Trend commentary
The five-year series is a complete boom-bust cycle. Revenue more than doubled in FY2022 on COVID testing (lab services were 77.6% of H1 2022 revenue), then collapsed 80% in FY2023 as testing ended. FY2024 combined three negatives: (i) the end of residual COVID revenue, (ii) HPV VBP price cuts, and (iii) large credit impairments on government receivables plus reversal of deferred tax assets, producing a RMB 655 M attributable loss. FY2025 revenue fell another 17.9% because of the first full year of HPV VBP and the 3%→13% VAT change on self-produced reagents, but the loss narrowed 80% as credit impairments fell by RMB 573 M. The inflection to profitability in H1 2026 rests on cost cuts and provisioning reversals rather than top-line growth (revenue still −4.7%).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Ownership | Segment | Notes (source) |
|---|---|---|---|
Chaozhou Kaipu Biochemical Co., Ltd. (凯普化学) | 100% | MDx products | National "little giant" specialised SME; H1 2026 net profit RMB 47.09 M (+151.98%) (2026 Interim) |
Guangzhou Kaipu Medical Laboratory Development Co., Ltd. (凯普医学检验) | 81.10% | Lab services | H1 2026 net loss RMB 29.94 M, loss narrowed by RMB 133.42 M YoY (2026 Interim) |
Hong Kong Molecular Pathology Laboratory Ltd. (香港检验中心) | Controlled | Lab services | Total assets RMB 770.0 M at 30 Jun 2026 (2026 Interim) |
Hybribio (Hong Kong) (凯普生物(香港)) | 100% | Trading/investment | Total assets RMB 1,441.8 M; H1 2026 net profit RMB 24.40 M, mainly FX gains |
Hong Kong Kaipu Biotech Co., Ltd. | 100% | Trading | Total assets RMB 10.3 M |
Guangzhou Kaipu Medicine Technology Co., Ltd. (凯普医药) | 100% | R&D | Joint research centre with Xiamen University |
Guangzhou Kaipu Biotechnology Co., Ltd. | 100% | R&D / drug project | Anti-HPV drug project co-implementer |
Guangzhou Kaipu Pharmaceutical Manufacturing Co., Ltd. | 100% | Drug manufacturing | Added as anti-HPV drug implementer Nov 2024 |
Guangdong Kaipu Medical Technology Industry Co., Ltd. | 100% | Medical Science Park | Borrower under syndicated loan; 100% equity pledged (2026 Interim) |
Chaozhou Kaipu Kanghe Hospital | Group-operated | Medical services | 100 of 200 planned beds open |
Revenue by Segment
| Segment (CNY Mn) | H1 2021 | H1 2022 | H1 2026 |
|---|---|---|---|
Molecular diagnostic products revenue | 445.0 | 637.3 | 184.0 |
Medical laboratory services revenue | 853.0 | 2,205.0 | 95.46 |
Medical services (hospital) revenue | — | — | 20.90 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment gross margin (%)
| Segment gross margin (%) | H1 2022 | H1 2026 |
|---|---|---|
Molecular diagnostic products | 74.37 | 74.64 |
Medical laboratory services | 67.05 | 13.58 |
Medical services (hospital) | — | -38.40 |
Group | — | 47.34 |
Segment Overview
| Segment | Revenue CNY Mn | % of total | Gross profit CNY Mn |
|---|---|---|---|
Molecular diagnostics | 184.0 | 61.3% | 137.0 |
Lab services | 95.46 | 31.8% | 12.97 |
Medical services | 20.90 | 7.0% | −8.03 |
Total | 300.0 | 100% | 142.0 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (CNY Mn) | 2,673.0 | 5,597.0 | 1,104.5 | 815.5 | 669.6 |
Revenue YoY growth (%) | — | 109.4 | -80.3 | -26.2 | -17.9 |
Gross profit (CNY Mn) | — | — | — | 388.8 | 304.5 |
Gross margin (%) | — | — | — | 47.7 | 45.5 |
Net profit incl. minorities (CNY Mn) | — | — | — | -950.4 | -182.3 |
Net profit attributable to shareholders (CNY Mn) | 852.5 | 1,726.0 | 140.5 | -654.9 | -130.9 |
Net profit attributable, excl. non-recurring (CNY Mn) | 841.1 | 1,734.5 | 113.2 | -659.7 | -171.0 |
Net margin, attributable (%) (calc.) | 31.9 | 30.8 | 12.7 | -80.3 | -19.6 |
Basic EPS (MYR Bn) | — | 2.62 | 0.25 | -1.02 | -0.21 |
Diluted EPS (MYR Bn) | — | 2.62 | 0.25 | -1.02 | -0.21 |
Weighted ROE (%) | — | 42.35 | 2.88 | -14.62 | -3.34 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|---|---|---|
Revenue (CNY Mn) | 183.1 | 225.8 | 201.4 | 205.3 | 134.1 | 180.9 | 170.9 | 183.8 |
Attributable net profit (CNY Mn) | -14.4 | -62.6 | -185.0 | -393.0 | -27.3 | -62.3 | -38.1 | -3.3 |
Operating cash flow (CNY Mn) | -64.1 | 30.8 | 77.6 | 34.4 | 46.9 | 8.5 | 65.8 | 220.4 |
Income Statement (Half-Yearly)
| Line item (CNY Mn) | H1 2025 | H1 2026 | YoY |
|---|---|---|---|
Revenue | 315.0 | 300.0 | -4.7% |
Cost of revenue | 167.0 | 158.0 | -5.4% |
Selling expense | 90.7 | 49.1 | -45.9% |
Admin expense | 101.2 | 95.3 | -5.8% |
Financial expense (negative = income) | -21.8 | -37.7 | FX gain on RMB appreciation |
R&D investment | 41.5 | 34.0 | -18.2% |
Credit impairment (positive = reversal) | -57.6 | 30.4 | reversal of receivable allowances |
Asset impairment | -10.9 | -0.4 | — |
Fair-value gains | 4.4 | 10.1 | revaluation of equity stakes |
Income tax | 10.0 | 15.0 | +50.5% |
Net profit incl. minorities | -137.1 | 25.4 | — |
Net profit attributable | -89.6 | 31.3 | — |
Operating cash flow | 55.4 | 70.7 | +27.6% |
Investing cash flow | 258.8 | -129.2 | equity investments and capex |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (CNY Mn) | 4,239.5 | 6,741.2 | 5,725.8 | 4,623.0 | 4,147.7 |
Equity attributable to shareholders (CNY Mn) | 3,194.6 | 4,907.2 | 4,861.3 | 4,109.4 | 3,748.4 |
Equity / total assets (%) (calc.) | 75.4 | 72.8 | 84.9 | 88.9 | 90.4 |
Book value per share (MYR Bn) | — | 7.94 | 9.07 | 6.30 | 5.87 |
Financial Analysis
| Item | Value | Date / source |
|---|---|---|
Cash, time deposits and structured deposits | RMB 1,038.7 M | 31 Dec 2025, FY2025 AR |
Cash & cash equivalents (cash-flow statement basis) | RMB 708.0 M | 31 Dec 2025, CFI.cn |
Cash & cash equivalents | RMB 388.9 M | 31 Mar 2026 (shift into wealth-management products) |
Wealth-management balance | RMB 638.0 M (of which RMB 140 M raised funds) | 30 Jun 2026, 2026 Interim |
Short-term borrowings | RMB 1.0 M (vs RMB 21.6 M end-2024) | 30 Sep 2025, Q3 2025 report |
Long-term borrowings | RMB 95.6 M (vs RMB 52.8 M end-2024), mainly special buyback loan | 30 Sep 2025 |
Treasury stock | RMB 110.1 M (vs RMB 65.1 M end-2024) | 30 Sep 2025 |
Accounts receivable — gross | RMB 1,645.3 M | 31 Dec 2025 |
Allowance for doubtful accounts | RMB 948.3 M | 31 Dec 2025 |
Accounts receivable — net | RMB 697.0 M | 31 Dec 2025 |
Of which pandemic-era (2020–22) receivables, gross / net | RMB 1,075.1 M / RMB 231.3 M | 31 Dec 2025 |
Goodwill | ~RMB 5.1 M | Q1 2026 (SZSE.io) |
Debt-to-assets ratio | 11.93% | Q1 2026 (SZSE.io) |
Factored receivables (restricted) | RMB 10.1 M | 30 Jun 2026 |
Undistributed profit | RMB 2,332.2 M | FY2025 (cited in SZSE investor Q&A) |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (CNY Mn) | 631.3 | 1,309.2 | 319.6 | 78.8 | 341.6 |
OCF / attributable net profit (x) (calc.) | 0.74 | 0.76 | 2.28 | — | — |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE, weighted (%) | 42.35 | 2.88 | -14.62 | -3.34 |
ROA, attributable NI / avg total assets (%) (calc.) | 31.4 | 2.3 | -12.7 | -3.0 |
Asset turnover, revenue / avg total assets (x) (calc.) | 1.02 | 0.18 | 0.16 | 0.15 |
Revenue by Region and Revenue by Region (%)
| Region | H1 2022 | H1 2026 |
|---|---|---|
Domestic revenue (CNY Mn) | 1,962.0 | 287.0 |
Overseas revenue (CNY Mn) | 880.2 | 13.3 |
Overseas share of revenue (%) | 31.0 | 4.4 |
Capital Markets
| Item | Value | Date / source |
|---|---|---|
Total shares | ~646.5 M | 2026, Sohu/CFI.cn |
Tradable A-shares | ~630 M | Aug 2026, CFI.cn |
Last verified close | RMB 6.15 | mid-Aug 2026, CFI.cn |
Buyback execution range | RMB 5.35–6.32 | Jul–Sep 2026 |
GM purchase prices | RMB 4.53–4.99 | Jan–Jul 2026 |
IPO price | RMB 18.39 (unadjusted) | Apr 2017 |
Book value per share | RMB 5.76 | 30 Jun 2026 |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market cap | ~RMB 3.98 bn | 646.5 M × RMB 6.15 |
P/B | ~1.07x | BVPS RMB 5.76 (Jun 2026) |
P/S (TTM) | ~6.1x | TTM revenue RMB 654.6 M (FY2025 − H1 2025 + H1 2026) |
EV/Sales (TTM) | ~4.5x | EV ≈ market cap − ~RMB 1.0 bn net cash (end-2025 basis) |
EV/EBITDA | Not computed | — |
Capital Markets — FY2024 dividend
| Item | Detail |
|---|---|
FY2024 dividend | None (no cash dividend, no bonus shares, no capitalisation) |
2025 buyback | Treasury stock rose from RMB 65.1 M (end-2024) to RMB 110.1 M (Sep 2025), financed partly by special buyback loan |
2026 buyback | Approved 23 Jul 2026; RMB 75–150 M; max price RMB 7.84; 3-month term to 22 Oct 2026; 21.5736 M shares (3.34%) for RMB 125 M by 30 Sep 2026; repurchased shares to be sold via centralised bidding 12 months after completion and within 3 years, otherwise cancelled |
Analyst Conclusions
Management guidance
No numerical guidance. Management describes FY2025 as the first full year of HPV VBP with its effect "fully released", expects lab-segment cost control to improve in 2026, and targets higher overall profitability through new-product expansion, specialty lab testing, hospital upgrades and receivable collection (FY2025 AR).
Bull case
-
Receivable optionality: gross pandemic receivables of RMB 1,075 M are carried at RMB 231 M; with national debt-swap funding, even partial recovery above book drives impairment reversals (already RMB 30.4 M in H1 2026) and cash inflows (FY2025 cash collected RMB 1,078 M).
-
Base effects and mix: VBP is fully in the base; the 74.6% gross-margin reagent business, with non-VBP HPV triage, pharmacogenomics (~RMB 25 M, fast-growing) and new birth-defect assays, can return revenue to growth.
-
Valuation floor: P/B ~1.1x with ~RMB 1 bn net cash (~25% of market cap), 3.34% buyback, and GM insider buying provide downside support.
Bear case
-
No organic growth yet: revenue −17.9% in FY2025 and −4.7% in H1 2026; gross profit fell YoY in H1 2026.
-
Low-quality profits: H1 2026 profit relied on impairment reversals, halved selling expense, FX and fair-value gains; core lab and hospital segments remain loss-making.
-
Capital allocation: cash directed to non-core robotics, AI psychology, cultural media and donations while paying no dividend; repurchased shares are slated for resale rather than cancellation.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing |
|---|---|
| Buyback completion and total size | 22 Oct 2026 |
| Q3 2026 report: revenue trajectory, impairment reversals | Late Oct 2026 |
| Chloroquine phosphate gel Phase III initiation | 2026–27 |
| Registrations: norovirus, vaginal microbiome; trial readouts for bladder/NPC methylation, SMA, HBV high-sensitivity | 2026–27 |
| Amisen HK IPO outcome (fair-value gain) | Pending |
| Further lab closures/consolidation; lab subsidiary breakeven | Ongoing |
| Kanghe hospital: linac installation, new departments, revenue scale | 2026–27 |
| FY2026 annual report and dividend decision | Apr 2027 |
| Any new VBP rounds touching STD, thalassaemia or other assays | Policy-dependent |
| Shareholder reductions by Yunnan Zhonghezhi/Guotiao fund | Ongoing |
Analyst verdict
Hybribio is a company emerging from a classic pandemic hangover, and the H1 2026 return to profit should be read as the end of the write-down phase rather than the start of a growth phase. The core asset—a high-margin, evidence-rich HPV and women's-health reagent franchise with leading VBP volume—remains intact and continues to throw off cash, as FY2025 operating cash flow of RMB 341.6 M against a reported loss demonstrates. The balance sheet is the company's best defence: about RMB 1 bn of cash and deposits, negligible debt, and receivables that have already been written down by RMB 948 M, leaving recovery upside rather than further downside on the pandemic book.
What is missing is evidence of organic revenue growth. Molecular diagnostics revenue has not yet stabilised under VBP and the VAT change, the lab network still operates at single-to-low-teens gross margins, and the hospital will take years to scale. Earnings in 2026 are being supported by provision releases, cost cuts and FX—none of which is repeatable indefinitely. Capital allocation is also a legitimate concern: investments in robotics, AI psychology and cultural media, alongside donations, sit awkwardly beside a no-dividend policy, and repurchased shares are earmarked for resale rather than cancellation.
At roughly 1.1x book and about 4.5x EV/sales on our estimates, the market already prices the company as an ex-growth asset with cash backing. The risk/reward is therefore asymmetric to the upside only if three things happen within 12–18 months: HPV triage and pharmacogenomic products reignite reagent growth, the lab subsidiary approaches breakeven after closures, and receivable recoveries continue at FY2025's pace. Until revenue turns positive on a full-year basis, we would characterise Hybribio as a balance-sheet-supported special situation rather than a quality compounder, with the Q3 2026 report and FY2026 dividend decision as the next tests of management's credibility.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Notes | Source |
|---|---|---|---|
Guan Qiaozhong (管乔中) | Chairman; legal representative; responsible person signing financial statements | Founder-chairman; chaired 2025 AGM (19 May 2026) | FY2024/2025 ARs; AGM resolution 2026-038 |
Wang Jianyu (王建瑜) | Director, General Manager; one of the actual controllers | Foreign (Hong Kong-resident) natural person; 1.69% direct stake end-2025 rising to 2.71% by 23 Jul 2026; mother of Guan Zhisheng | FY2025 AR; announcement 2026-049, 2026-054 |
Guan Zhisheng (管秩生) | One of the actual controllers; 0.56% direct holder | — | FY2025 AR |
Li Qinghui (李庆辉) | Head of accounting (CFO-equivalent) | Signs financial statements | FY2024 AR; 2025 Interim |
Luo Cuihong (罗翠红) | Head of accounting department | — | FY2024 AR |
Chen Yi (陈毅) | Board Secretary | IR contact | FY2025 AR |
Yuan Xian (袁娴) | Securities Affairs Representative | — | FY2025 AR |
Prof. Li Xiaochuan (李晓川) | Chief Medical Officer; head of Kanghe oncology centre | Tenured professor of radiation oncology, Medical College of Wisconsin | FY2025 AR |
Dr. Xie Longxu (谢龙旭) | Chief Scientist | Co-author of a 2020 Chinese Journal of Oncology award-winning HPV12+2 screening paper; disposed of shares in Jan 2026 | FY2025 AR; Sohu insider-trading list |
Shareholding Trend
| Shareholder | Type | 31 Dec 2025 stake | 23 Jul 2026 stake |
|---|---|---|---|
Hong Kong Technology Venture Co., Ltd. (香港科技创业股份有限公司) | Overseas corporate (controlling shareholder) | 29.88% (193.20 M shares) | 29.88% |
Yunnan Zhonghezhi Enterprise Management Co., Ltd. | Domestic non-state | 6.21% (25.93 M shares pledged) | 5.00% |
Shenzhen Guotiao-CMB M&A Equity Investment Fund (LP) | Domestic non-state (state-linked fund) | 4.76% | 3.98% |
Yunnan Yanchen Enterprise Management Co., Ltd. | Domestic non-state | 2.26% (9.89 M pledged) | 1.04% |
Wang Jianyu | Overseas individual (controller) | 1.69% | 2.71% |
Beijing Xinweigang Technology Co., Ltd. | Domestic | not in top 10 | 1.56% |
Long Xifu | Domestic individual | 0.59% | not in top 10 |
Zhao Xuefang | Domestic individual | 0.57% | 0.58% |
Guan Zhisheng | Overseas individual (controller) | 0.56% | 0.56% |
Qi Yufeng | Domestic individual | 0.49% | not in top 10 |
Yongying CSI All-Share Medical Devices ETF | Fund | 0.30% | 0.44% |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs. Hybribio |
|---|---|---|
HPV / women's-health MDx | Daan Gene (达安基因, 002030.SZ) | Broad PCR MDx player, competitor in HPV VBP |
HPV / infectious MDx | Sansure Biotech (圣湘生物, 688289.SH) | Larger, diversifying via M&A (growth hormone, HLA); FY2025 revenue RMB 1,642 M, net profit RMB 199 M |
HPV / genomics | BGI Genomics (华大基因) | Sequencing-based screening incl. HPV |
HPV / multiplex | Tellgen (透景生命) | HPV and tumour marker panels |
Global HPV | Roche Diagnostics (cobas HPV) | Premium hospital segment, automation |
Global HPV | Hologic (Aptima HPV mRNA) | mRNA-based triage competitor |
Global HPV/MDx | Qiagen; Becton Dickinson (Onclarity); Abbott | Global brands in tertiary hospitals |
Thalassaemia/deafness genetics | Yaneng Bio (亚能生物); CapitalBio | Direct competitors in hereditary screening |
ICL | KingMed Diagnostics (金域医学, 603882.SH) | Market leader in Chinese ICL |
ICL | Dian Diagnostics (迪安诊断, 300244.SZ) | No.2 ICL; FY2025 revenue RMB 10,096 M (−17.2%), attributable profit RMB 44 M |
ICL | Adicon (艾迪康) | National ICL chain |
Peer Comparison FY2025
| Metric | Hybribio | Sansure Biotech | Dian Diagnostics |
|---|---|---|---|
Revenue | 669.6 | 1,642 | 10,096 |
Revenue growth (%) | -17.9 | 12.6 | -17.2 |
Attributable net profit | -130.9 | 199 | 44 |
Net margin (%) | -19.6 | 12.1 | 0.4 |
R&D % of revenue | 11.5 | — | — |
Recent Developments
--



